Medpace Holdings, Inc. (MEDP) stock
Close on Nov 13, 2026Market cap $18.29BP/E 36.3Yield –
Medpace Holdings, Inc. grew revenue 20.4% to $2.84B over the twelve months to Sep 30, 2026. Operating income rose 19.7% to $607.14M, moving the operating margin from 21.5% to 21.4%. Free cash flow was $667.63M, down 1.4% from a year earlier. At the latest close the market valued the company at $18.29B, 36.3 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $18.29B
- P/E ratio
- 36.3
- Price to sales
- 6.44
- Price to book
- 31.27
- Dividend yield
- –
- Free cash flow yield
- 3.65%
Fundamentals
- Revenue
- $2.84B
- Net income
- $517.83M
- EPS, diluted
- $18.03
- Free cash flow
- $667.63M
- Book value per share
- $20.62
- Diluted shares
- 28M
Trading
- Next earnings
- Feb 8, 2027 (estimated, after the close)
- Previous close
- $656.84
- Open
- $660.25
- Day's range
- $644.77 – $660.25
- Volume
- 105,452
- Average volume (20 days)
- 306,492
- Index membership
- S&P MidCap 400 (since Nov 2020), Russell 1000 (since Jun 2023), Russell 3000
- Beta (5 years)
- 1.39
- 52-week range
- $373.00 – $693.97
- RSI (14 days)
- 52.0
- Volatility (1 year)
- 44.1%
- Relative volume
- 0.37×
- WACC
- 12.0%
On 1 of our idea list: Buyback cannibals
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | MEDP | S&P 500 | Difference | MEDP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +7.2% | -3.0% | +10.3 pts | ||
| 3 months | +12.4% | -2.8% | +15.2 pts | ||
| Year to date | +16.4% | +11.5% | +4.9 pts | ||
| 1 year | +10.6% | +13.5% | −2.9 pts | ||
| 3 years | +137.0% | +77.7% | +59.3 pts | +33.3% | +21.1% |
| 5 years | +194.7% | +72.6% | +122.1 pts | +24.1% | +11.5% |
| 10 years | +1803.8% | +308.2% | +1495.6 pts | +34.3% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Medpace filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Medpace
Services-Commercial Physical & Biological Research
Medpace Holdings, Inc. is a clinical contract research organization that provides outsourced clinical development services across Phase I through Phase IV trials. Its offerings serve biotechnology, pharmaceutical, and medical device companies, focusing especially on small and mid-sized biopharmaceutical developers. The company provides medical study design, trial execution via its proprietary ClinTrak software, patient recruitment, regulatory compliance, biometrics, pharmacovigilance, and quality assurance. Additionally, it provides specialized laboratory support through central, bioanalytical, and core imaging and cardiovascular facilities, alongside research clinics that evaluate therapeutics in healthy volunteers and targeted patient groups.
Company profile, executives and historyMedpace stock: common questions
What is Medpace's stock price?
MEDP closed at $653.94 on Nov 13, 2026, down 0.44% on the day. Over the past 52 weeks it traded between $373.00 and $693.97.
What is Medpace's market cap?
Medpace was worth $18.29B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is MEDP's P/E ratio?
MEDP trades at 36.3 times earnings, based on diluted earnings per share of $18.03 over the twelve months to Sep 30, 2026.
How much revenue does Medpace make?
Medpace reported revenue of $2.84B for the twelve months to Sep 30, 2026, up 20.4% from a year earlier.
Does Medpace pay a dividend?
No. Medpace has not paid a cash dividend over the last twelve months.
When does Medpace report earnings next?
Medpace is expected to report Q4 FY2026 results on Feb 8, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has MEDP stock performed over the past year?
Including dividends, MEDP returned +10.6% over the past year, against +13.5% for the S&P 500.
How many MEDP shares are sold short?
1M shares were sold short at the latest FINRA report, 6.18% of the float, or 3.5 days of average trading volume.
Who are Medpace's competitors?
Companies most similar to Medpace by business, industry and size include ICLR, CRL, IQV, INCY, FTRE.
See a number that looks wrong?